Teva Pharmaceutical Industries (TEVA) Revenue & Revenue Breakdown
Teva Pharmaceutical Industries Revenue Highlights
Latest Revenue (Y)
$15.85B
Latest Revenue (Q)
$4.16B
Main Segment (Y)
International Markets
Main Geography (Y)
North America
Teva Pharmaceutical Industries Revenue by Period
Teva Pharmaceutical Industries Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $15.85B | 6.17% |
| 2022-12-31 | $14.93B | -6.00% |
| 2021-12-31 | $15.88B | -4.68% |
| 2020-12-31 | $16.66B | -1.36% |
| 2019-12-31 | $16.89B | -10.43% |
| 2018-12-31 | $18.85B | -15.77% |
| 2017-12-31 | $22.39B | 2.20% |
| 2016-12-31 | $21.90B | 11.45% |
| 2015-12-31 | $19.65B | -3.06% |
| 2014-12-31 | $20.27B | -0.21% |
| 2013-12-31 | $20.31B | -0.01% |
| 2012-12-31 | $20.32B | 10.95% |
| 2011-12-31 | $18.31B | 13.59% |
| 2010-12-31 | $16.12B | 15.99% |
| 2009-12-31 | $13.90B | 25.39% |
| 2008-12-31 | $11.09B | 17.83% |
| 2007-12-31 | $9.41B | 11.89% |
| 2006-12-31 | $8.41B | 60.14% |
| 2005-12-31 | $5.25B | 9.41% |
| 2004-12-31 | $4.80B | 46.47% |
| 2003-12-31 | $3.28B | 30.09% |
| 2002-12-31 | $2.52B | 21.24% |
| 2001-12-31 | $2.08B | 18.72% |
| 2000-12-31 | $1.75B | 36.45% |
| 1999-12-31 | $1.28B | 14.92% |
| 1998-12-31 | $1.12B | -0.09% |
| 1997-12-31 | $1.12B | 17.10% |
| 1996-12-31 | $953.80M | 42.85% |
| 1995-12-31 | $667.70M | 13.61% |
| 1994-12-31 | $587.70M | 17.07% |
| 1993-12-31 | $502.00M | - |
Teva Pharmaceutical Industries generated $15.85B in revenue during NA 2023, up 6.17% compared to the previous quarter, and up 84.05% compared to the same period a year ago.
Teva Pharmaceutical Industries Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $4.16B | 8.66% |
| 2024-03-31 | $3.83B | -14.02% |
| 2023-12-31 | $4.46B | 15.77% |
| 2023-09-30 | $3.85B | -0.72% |
| 2023-06-30 | $3.88B | 5.93% |
| 2023-03-31 | $3.66B | -5.74% |
| 2022-12-31 | $3.88B | 8.04% |
| 2022-09-30 | $3.60B | -5.02% |
| 2022-06-30 | $3.79B | 3.39% |
| 2022-03-31 | $3.66B | -10.71% |
| 2021-12-31 | $4.10B | 5.51% |
| 2021-09-30 | $3.89B | -0.61% |
| 2021-06-30 | $3.91B | -1.81% |
| 2021-03-31 | $3.98B | -10.56% |
| 2020-12-31 | $4.45B | 11.92% |
| 2020-09-30 | $3.98B | 2.79% |
| 2020-06-30 | $3.87B | -11.18% |
| 2020-03-31 | $4.36B | -2.48% |
| 2019-12-31 | $4.47B | 4.78% |
| 2019-09-30 | $4.26B | -1.68% |
| 2019-06-30 | $4.34B | 0.98% |
| 2019-03-31 | $4.29B | -5.79% |
| 2018-12-31 | $4.56B | 0.66% |
| 2018-09-30 | $4.53B | -3.66% |
| 2018-06-30 | $4.70B | -7.19% |
| 2018-03-31 | $5.07B | -7.22% |
| 2017-12-31 | $5.46B | -2.69% |
| 2017-09-30 | $5.61B | -1.34% |
| 2017-06-30 | $5.69B | 0.99% |
| 2017-03-31 | $5.63B | -13.28% |
| 2016-12-31 | $6.49B | 16.70% |
| 2016-09-30 | $5.56B | 10.42% |
| 2016-06-30 | $5.04B | 4.74% |
| 2016-03-31 | $4.81B | -1.45% |
| 2015-12-31 | $4.88B | 1.20% |
| 2015-09-30 | $4.82B | -2.88% |
| 2015-06-30 | $4.97B | -0.32% |
| 2015-03-31 | $4.98B | -3.60% |
| 2014-12-31 | $5.17B | 2.17% |
| 2014-09-30 | $5.06B | 0.26% |
| 2014-06-30 | $5.04B | 0.88% |
| 2014-03-31 | $5.00B | -7.90% |
| 2013-12-31 | $5.43B | 7.33% |
| 2013-09-30 | $5.06B | 2.74% |
| 2013-06-30 | $4.92B | 0.47% |
| 2013-03-31 | $4.90B | -6.63% |
| 2012-12-31 | $5.25B | 5.57% |
| 2012-09-30 | $4.97B | -0.44% |
| 2012-06-30 | $4.99B | -2.12% |
| 2012-03-31 | $5.10B | -10.11% |
| 2011-12-31 | $5.68B | 30.66% |
| 2011-09-30 | $4.34B | 3.13% |
| 2011-06-30 | $4.21B | 3.24% |
| 2011-03-31 | $4.08B | -7.65% |
| 2010-12-31 | $4.42B | 3.95% |
| 2010-09-30 | $4.25B | 11.84% |
| 2010-06-30 | $3.80B | 4.02% |
| 2010-03-31 | $3.65B | -3.92% |
| 2009-12-31 | $3.80B | 7.10% |
| 2009-09-30 | $3.55B | 4.41% |
| 2009-06-30 | $3.40B | 8.04% |
| 2009-03-31 | $3.15B | 10.50% |
| 2008-12-31 | $2.85B | 0.21% |
| 2008-09-30 | $2.84B | 0.67% |
| 2008-06-30 | $2.82B | 9.76% |
| 2008-03-31 | $2.57B | - |
Teva Pharmaceutical Industries generated $4.16B in revenue during Q2 2024, up 8.66% compared to the previous quarter, and up 113.74% compared to the same period a year ago.
Teva Pharmaceutical Industries Revenue Breakdown
Teva Pharmaceutical Industries Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| International Markets | $1.96B | $1.90B | $2.03B | $2.15B | $2.25B |
| Other Activities | $926.00M | $1.04B | $1.15B | $1.30B | $1.30B |
Teva Pharmaceutical Industries's latest annual revenue breakdown by segment (product or service), as of Dec 23: International Markets (67.89%), and Other Activities (32.11%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Distribution Service | $382.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Product and Service, Other | $106.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Product | $3.64B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| License | $36.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Activities | - | $462.00M | $245.00M | $219.00M | $272.00M | $241.00M | $257.00M | $275.00M | $302.00M | $262.00M | $298.00M | $289.00M | $345.00M | $316.00M | $335.00M | $307.00M | $332.00M | $314.00M | - | - |
| International Markets | - | $987.00M | $479.00M | $492.00M | $481.00M | $475.00M | $454.00M | $492.00M | $527.00M | $530.00M | $485.00M | $490.00M | $572.00M | $529.00M | $488.00M | $565.00M | $101.00M | $736.00M | - | - |
| Austedo | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $96.00M | - |
| AJOVY | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $23.00M | - |
| Anda | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $351.00M | - |
| Pro Air | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $65.00M | - |
| QVAR | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $60.00M | - |
| TREANDA and BENDEKA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $115.00M | - |
| Distribution | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $151.00M |
Teva Pharmaceutical Industries's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Product (87.42%), Distribution Service (9.17%), Product and Service, Other (2.55%), and License (0.86%).
Teva Pharmaceutical Industries Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| North America | $8.12B | $5.83B | $6.39B | $6.90B | $6.94B |
| Europe | $4.84B | $4.46B | $4.81B | $4.74B | $4.77B |
Teva Pharmaceutical Industries's latest annual revenue breakdown by geography, as of Dec 23: North America (62.68%), and Europe (37.32%).
Quarterly Revenue by Country
| Country | Jun 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | $2.11B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Europe | $1.21B | $2.51B | $1.15B | $1.18B | $1.16B | $1.03B | $1.13B | $1.13B | $1.25B | $1.20B | $1.19B | $1.18B | $1.25B | $7.00M | $1.00B | $1.37B | $7.00M | $1.15B | $1.17B | $1.26B |
| North America | - | $5.23B | $1.58B | $1.32B | $1.53B | $1.39B | $1.54B | $1.38B | $1.62B | $1.49B | $1.62B | $1.67B | $1.96B | $1.66B | $1.66B | $1.63B | $1.94B | $1.67B | $1.69B | $1.64B |
Teva Pharmaceutical Industries's latest quarterly revenue breakdown by geography, as of Jun 24: UNITED STATES (63.50%), and Europe (36.50%).
Teva Pharmaceutical Industries Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| TAK | Takeda Pharmaceutical Company | $4.26T | $1.05T |
| TEVA | Teva Pharmaceutical Industries | $15.85B | $4.16B |
| VTRS | Viatris | $15.43B | $3.66B |
| HLN | Haleon | $11.30B | $2.92B |
| BHC | Bausch Health Companies | $8.76B | $2.40B |
| ZTS | Zoetis | $8.54B | $2.36B |
| ELAN | Elanco Animal Health | $4.42B | $1.21B |
| CTLT | Catalent | $4.38B | $1.07B |
| SNDL | SNDL | $909.01M | $197.75M |
| TLRY | Tilray Brands | $788.94M | $188.34M |
| CGC | Canopy Growth | $297.15M | $75.78M |
| ACB | Aurora Cannabis | $233.29M | $64.42M |
| HEXO | HEXO | $191.10M | $21.59M |
| LFCR | Lifecore Biomedical | $128.26M | $35.70M |
| CRON | Cronos Group | $120.27M | $38.68M |
| LSDI | Lucy Scientific Discovery | $7.05K | $9.68K |
| SHPH | Shuttle Pharmaceuticals | - | - |
TEVA Revenue FAQ
What is Teva Pharmaceutical Industries’s yearly revenue?
Teva Pharmaceutical Industries's yearly revenue for 2023 was $15.85B, representing an increase of 6.17% compared to 2022. The company's yearly revenue for 2022 was $14.92B, representing a decrease of -6.00% compared to 2021. TEVA's yearly revenue for 2021 was $15.88B, representing a decrease of -4.68% compared to 2020.
What is Teva Pharmaceutical Industries’s quarterly revenue?
Teva Pharmaceutical Industries's quarterly revenue for Q2 2024 was $4.16B, a 8.66% increase from the previous quarter (Q1 2024), and a 7.37% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $3.83B, a -14.02% decrease from the previous quarter (Q4 2023), and a 4.67% increase year-over-year (Q1 2023). TEVA's quarterly revenue for Q4 2023 was $4.46B, a 15.77% increase from the previous quarter (Q3 2023), and a 14.75% increase year-over-year (Q4 2022).
What is Teva Pharmaceutical Industries’s revenue growth rate?
Teva Pharmaceutical Industries's revenue growth rate for the last 3 years (2021-2023) was -0.20%, and for the last 5 years (2019-2023) was -6.16%.
What are Teva Pharmaceutical Industries’s revenue streams?
Teva Pharmaceutical Industries's revenue streams in c 23 are International Markets, and Other Activities. International Markets generated $1.96B in revenue, accounting 67.89% of the company's total revenue, up 2.89% year-over-year. Other Activities generated $926M in revenue, accounting 32.11% of the company's total revenue, down -11.39% year-over-year.
What is Teva Pharmaceutical Industries’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Teva Pharmaceutical Industries was International Markets. This segment made a revenue of $1.96B, representing 67.89% of the company's total revenue.